Zobrazeno 51 - 60
of 281
pro vyhledávání: '"Hui K. Gan"'
Autor:
Andrea Mannucci, Adnan Nagrial, Catello Somma, Jason D. Lickliter, Jianjun Zou, Mark Voskoboynik, Michael Millward, Tarek Meniawy, Lianshan Zhang, Katherine Woods, Peter Grimison, Michael Lahn, Surein Arulananda, Hui K Gan, Pablo Fernandez-Penas, Andreas Behren, Bo Gao, Michelle Harrison, Howard Kallender, Stacey Luo
Publikováno v:
Drug Design, Development and Therapy. 14:1177-1189
Purpose Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal antibody. We report results from the First-in-Human Phase 1 trial of camrelizumab in Australian
Publikováno v:
Critical Reviews™ in Oncogenesis. 25:175-207
Human epidermal growth factor receptor 2 (HER2) oncogene addiction has led to the development of anti-HER2 therapies which have revolutionized the management of patients with HER2-positive cancers, with trastuzumab being the cornerstone of treatment
Autor:
Lakshmi Nayak, Nathan Standifer, Jorg Dietrich, Jennifer L. Clarke, Gavin P. Dunn, Michael Lim, Timothy Cloughesy, Hui K. Gan, Elizabeth Flagg, Elizabeth George, Sarah Gaffey, Julia Hayden, Christina Holcroft, Patrick Y. Wen, Mary Macri, Andrew J. Park, Toni Ricciardi, Aileen Ryan, Paul Schwarzenberger, Ralph Venhaus, Melissa de los Reyes, Nicholas M. Durham, Todd Creasy, Raymond Y. Huang, Thomas Kaley, David A. Reardon
Publikováno v:
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 12
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 12
Purpose: PD-L1 is upregulated in glioblastoma and supports immunosuppression. We evaluated PD-L1 blockade with durvalumab among glioblastoma cohorts and investigated potential biomarkers. Patients and Methods: MGMT unmethylated newly diagnosed patien
Autor:
Lucy F. Stead, Mustafa Khasraw, Michael Weller, Frederick S. Varn, Nazia Ahmed, Annemiek M E Walenkamp, Houtan Noushmehr, Erwin G. Van Meir, Tathiane M. Malta, Luciano Garofano, Jason T. Huse, David Ormond, Colin Watts, Pieter Wesseling, Thais S. Sabedot, Emre Kocakavuk, Floris P. Barthel, Taylor Wade, Roel G.W. Verhaak, Spyridon Bakas, Jill S. Barnholtz-Sloan, Sun Ha Paek, Kevin M. Johnson, Tobias Weiss, Hui K Gan, Simona Migliozzi, Fulvio D'Angelo, Indrani Datta, Laila M. Poisson, Antonio Iavarone, Hoon Kim
Publikováno v:
Neuro Oncol
Diffuse glioma is characterized by a poor prognosis and a universal resistance to therapy, though the evolutionary processes behind this resistance remain unclear. The Glioma Longitudinal Analysis (GLASS) Consortium has previously demonstrated that t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a991e1416956193b224da692e3847b8
https://europepmc.org/articles/PMC8598702/
https://europepmc.org/articles/PMC8598702/
Publikováno v:
Cancers, Vol 13, Iss 5716, p 5716 (2021)
Cancers
Cancers
Simple Summary Radiotherapy (RT) is an effective treatment for head and neck squamous cell carcinoma (HNSCC). Concurrent RT with high dose cisplatin (100 mg/m2, days 1, 22, and 42) is the standard of care (SOC) for non-operative HNSCC in curative set
Autor:
Malaka Ameratunga, Yuliya Perchyonok, Diana Cao, Andrew Mark Scott, Eddie Lau, Graeme O'Keefe, Angela Rigopoulos, Sze Ting Lee, Andrew B. Lassman, David Maag, Hui K Gan, Sagun Parakh, Aidan Seow, Ingrid Burvenich, Erica Gomez
Publikováno v:
Neuro-oncology Advances
BackgroundThe adverse impact of increasing brain tumor size on the efficacy of antibody-drug conjugates (ADCs) was investigated preclinically then validated with clinical data.Methods—Preclinical studyThe impact of tumor size on ADC tumor delivery
Autor:
Sagun Parakh, Hui K Gan
Publikováno v:
Neurooncol Pract
Autor:
Bart A. Westerman, Bauke Ylstra, Peter A. E. Sillevis Smitt, Guido Reifenberger, Lucy F. Stead, Fulvio D'Angelo, Ann-Christin Hau, Frederick S. Varn, Sun Ha Paek, Johanna M. Niers, Indrani Datta, D. Ryan Ormond, Antonio Iavarone, Pieter Wesseling, Anna Lasorella, Kenneth Aldape, Michael Weller, Emre Kocakavuk, Laila M. Poisson, Spyridon Bakas, Annemiek M E Walenkamp, Tathiane M. Malta, Wies Vallentgoed, Houtan Noushmehr, Simona Migliozzi, Pim J. French, Mathilde C.M. Kouwenhoven, Hui K Gan, Martin J. van den Bent, Kevin C. Johnson, Erwin G. Van Meir, Tobias Weiss, Marion Smits, Luciano Garofano, Jill S. Barnholtz-Sloan, Mohammad Hasanain, Roel G.W. Verhaak, Mustafa Khasraw, Simone P. Niclou, Thais S. Sabedot
SummaryTumor adaptation or selection is thought to underlie therapy resistance of gliomas. To investigate the longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 143 matched initial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bc7b1fac81c575aa14e78b9cdab1c08
https://doi.org/10.1101/2021.08.09.455687
https://doi.org/10.1101/2021.08.09.455687
Publikováno v:
Journal of Clinical Neuroscience. 79:269-271
Pilocytic astrocytomas are World Health Organisation (WHO) grade I tumors, occurring predominantly supratentorially and in the pediatric population. Although the mainstay of treatment is local therapies such as surgery, targeted systemic therapies ma
Autor:
Sanjeev Deva, Michael Millward, Michael Friedlander, Hui K. Gan, Lisa G. Hovarth, Jong-Seok Lee, Andrew Hill, Shahneen Sandhu, Liang Liang, Jingwen Shi, Yun Zhang, Yang Shi, Xiaopeng Ma, Xikun Wu, Zhirong Shen, Jayesh Desai
Publikováno v:
Cancer Research. 82:LB511-LB511
Background: High tumor mutational burden (TMB-H) is associated with elevated neoantigen expression across tumors, linked with an improved response to PD-(L)1 inhibitors. Here we report data from the final analysis of a Phase 1 trial that enrolled pat